Business & Regulation

Trump continues to send shockwaves through the industry. We look at FDA disruption, tariffs, funding volatility, and more.

Many US researchers are at odds with the imposition of Trump’s political agendas. EU member states are looking to take advantage.

Our latest news roundup reports on Novartis’ new acquisition, an NIH grant for an Alzheimer’s disease vaccine, and more

Attorney Generals claim: “This administration is not streamlining the federal government; they are sabotaging it.”

From a love of history books to a love of CRISPR, Monika Paule tells us the story of her career and the origins of Caszyme.

As mental health disorders escalate, pharmaceutical innovators can harness advanced tools to accelerate much-needed treatments.

From Carl June to Peter Marks to Kiran Mazumdar-Shaw; check out our thought provoking interviews with some of the biggest names in the pharma field.

Our latest news roundup reports on Roche’s US investment, a lawsuit against Vertex Pharmaceuticals, and more.

EMA reflection paper considers elimination of routine comparative efficacy studies for biosimilars.

Trump signs executive order on lowering drug prices and amends Medicare price negotiation for small molecule drugs.